Efalizumab disrupts the interaction between which of the following adhesion molecules?
Agents targeting co-stimulatory molecules and under development for psoriasis include: Efalizumab, -A gainst CD11a (LFA-1), which blocks CD11a-ICAM-1 binding and may inhibit lymphocyte binding to endothelium the same mechanism. Alefacept - Inhibiting the normal CD2/LFA-3 interaction.
LFA-3 and ICAM-1
LFA-1 and ICAM-1
LFA-3 and ICAM-3
LFA-3 and CD2
Psoriasis